Preventing Heart Failure With Farxiga
Jul 28, 2020
Editor: David L. Joffe, BSPharm, CDE, FACA
Author: Zahra Hashemy, PharmD. Candidate, USF Taneja College of Pharmacy
The FDA has given a Fast Track Designation to accelerate study of how Farxiga may help reduction in mortality and heart failure after a heart attack.
Every year nearly seven million people have heart attacks across the world. Acute myocardial infarction (MI) or heart attack is a known cause of heart failure (H.F.). Patients who experience an MI followed by H.F. will have a higher mortality risk than those who present with H.F. upon hospital admission.
A phase III trial called DAPA-MI will evaluate the safety and efficacy of Farxiga to reduce heart failure risk and mortality after an MI. Due to this trial, the Food and Drug Administration (FDA) has granted Farxiga a Fast Track Designation. The FDA’s Fast Track program is designed to “accelerate the development and review of new medicines for the treatment of serious conditions where there is an unmet treatment need...."
Agreement to pay later is required for access to the full text of this article. You will be charged only after your use reaches $5.00 (US) of site content. The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.